|
1
|
Huang Z, Wen W, Zheng Y, Gao YT, Wu C, Bao
P, Wang C, Gu K, Peng P, Gong Y, et al: Breast cancer incidence and
mortality: Trends over 40 years among women in Shanghai, China. Ann
Oncol. Feb 18–2016.(Epub ahead of print). View Article : Google Scholar
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hulka BS and Moorman PG: Breast cancer:
Hormones and other risk factors. Maturitas. 38:103–113; discussion
113–116. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Autier P, Boniol M, La Vecchia C, Vatten
L, Gavin A, Héry C and Heanue M: Disparities in breast cancer
mortality trends between 30 European countries: Retrospective trend
analysis of WHO mortality database. BMJ. 341:c36202010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cianfrocca M and Goldstein LJ: Prognostic
and predictive factors in early-stage breast cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carlson RW and Stockdale FE: The clinical
biology of breast cancer. Annu Rev Med. 39:453–464. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Polednak AP: Survival of lymph
node-negative breast cancer patients in relation to number of lymph
nodes examined. Ann Surg. 237:163–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rao R, Euhus D, Mayo HG and Balch C:
Axillary node interventions in breast cancer: A systematic review.
JAMA. 310:1385–1394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fleissig A, Fallowfield LJ, Langridge CI,
Johnson L, Newcombe RG, Dixon JM, Kissin M and Mansel RE:
Post-operative arm morbidity and quality of life. Results of the
ALMANAC randomised trial comparing sentinel node biopsy with
standard axillary treatment in the management of patients with
early breast cancer. Breast Cancer Res Treat. 95:279–293. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Krag DN, Anderson SJ, Julian TB, Brown AM,
Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP,
Jalovec LM, et al: Sentinel-lymph-node resection compared with
conventional axillary-lymph-node dissection in clinically
node-negative patients with breast cancer: Overall survival
findings from the NSABP B-32 randomised phase 3 trial. Lancet
Oncol. 11:927–933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pesce C and Morrow M: The need for lymph
node dissection in nonmetastatic breast cancer. Annu Rev Med.
64:119–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burns KA and Korach KS: Estrogen receptors
and human disease: An update. Arch Toxicol. 86:1491–1504. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fisher B, Redmond C, Fisher ER and Caplan
R: Relative worth of estrogen or progesterone receptor and
pathologic characteristics of differentiation as indicators of
prognosis in node negative breast cancer patients: Findings from
National Surgical Adjuvant Breast and Bowel Project Protocol B-06.
J Clin Oncol. 6:1076–1087. 1988.PubMed/NCBI
|
|
14
|
Bentzon N, Düring M, Rasmussen BB,
Mouridsen H and Kroman N: Prognostic effect of estrogen receptor
status across age in primary breast cancer. Int J Cancer.
122:1089–1094. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hammond MEH, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College Of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harvey JM, Clark GM, Osborne CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481.
1999.PubMed/NCBI
|
|
17
|
Davies C, Godwin J, Gray R, Clarke M,
Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al:
Early Breast Cancer Trialists' Collaborative Group (EBCTCG):
Relevance of breast cancer hormone receptors and other factors to
the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horwitz KB and McGuire WL: Estrogen
control of progesterone receptor in human breast cancer.
Correlation with nuclear processing of estrogen receptor. J Biol
Chem. 253:2223–2228. 1978.PubMed/NCBI
|
|
19
|
Savouret JF, Bailly A, Misrahi M, Rauch C,
Redeuilh G, Chauchereau A and Milgrom E: Characterization of the
hormone responsive element involved in the regulation of the
progesterone receptor gene. EMBO J. 10:1875–1883. 1991.PubMed/NCBI
|
|
20
|
Purdie CA, Quinlan P, Jordan LB, Ashfield
A, Ogston S, Dewar JA and Thompson AM: Progesterone receptor
expression is an independent prognostic variable in early breast
cancer: A population-based study. Br J Cancer. 110:565–572. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: Prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pathmanathan N and Balleine RL: Ki67 and
proliferation in breast cancer. J Clin Pathol. 66:512–516. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Azambuja E, Cardoso F, de Castro G Jr,
Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D,
Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in
early breast cancer: A meta-analysis of published studies involving
12,155 patients. Br J Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: International Ki-67 in Breast Cancer Working Group: Assessment
of Ki67 in breast cancer: Recommendations from the International
Ki67 in Breast Cancer working group. J Natl Cancer Inst.
103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arteaga CL, Sliwkowski MX, Osborne CK,
Perez EA, Puglisi F and Gianni L: Treatment of HER2-positive breast
cancer: Current status and future perspectives. Nat Rev Clin Oncol.
9:16–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Winstanley J, Cooke T, Murray GD,
Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A,
Barraclough BR and Rudland PS: The long term prognostic
significance of c-erbB-2 in primary breast cancer. Br J Cancer.
63:447–450. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paterson MC, Dietrich KD, Danyluk J,
Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE,
McBlain WA, et al: Correlation between c-erbB-2 amplification and
risk of recurrent disease in node-negative breast cancer. Cancer
Res. 51:556–567. 1991.PubMed/NCBI
|
|
29
|
Yin W, Jiang Y, Shen Z, Shao Z and Lu J:
Trastuzumab in the adjuvant treatment of HER2-positive early breast
cancer patients: A meta-analysis of published randomized controlled
trials. PLoS One. 6:e210302011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rakha EA, Reis-Filho JS, Baehner F, Dabbs
DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani
SR, et al: Breast cancer prognostic classification in the molecular
era: The role of histological grade. Breast Cancer Res.
12:2072010.PubMed/NCBI
|
|
32
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th. John Wiley &
Sons, Ltd., Publication; Oxford: 2009
|
|
33
|
Kiely BE, Soon YY, Tattersall MHN and
Stockler MR: How long have I got? Estimating typical, best-case,
and worst-case scenarios for patients starting first-line
chemotherapy for metastatic breast cancer: A systematic review of
recent randomized trials. J Clin Oncol. 29:456–463. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carter CL, Allen C and Henson DE: Relation
of tumor size, lymph node status, and survival in 24,740 breast
cancer cases. Cancer. 63:181–187. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Koscielny S, Tubiana M, Lê MG, Valleron
AJ, Mouriesse H, Contesso G and Sarrazin D: Breast cancer:
Relationship between the size of the primary tumour and the
probability of metastatic dissemination. Br J Cancer. 49:709–715.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Benson JR, Jatoi I, Keisch M, Esteva FJ,
Makris A and Jordan VC: Early breast cancer. Lancet. 373:1463–1479.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Galea MH, Blamey RW, Elston CE and Ellis
IO: The Nottingham Prognostic Index in primary breast cancer.
Breast Cancer Res Treat. 22:207–219. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Frkovic-Grazio S and Bracko M: Long term
prognostic value of Nottingham histological grade and its
components in early (pT1N0M0) breast carcinoma. J Clin Pathol.
55:88–92. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Prat A and Perou CM: Deconstructing the
molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Haldosén LA, Zhao C and Dahlman-Wright K:
Estrogen receptor beta in breast cancer. Mol Cell Endocrinol.
382:665–672. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rizza P, Barone I, Zito D, Giordano F,
Lanzino M, De Amicis F, Mauro L, Sisci D, Catalano S, Wright K
Dahlman, et al: Estrogen receptor beta as a novel target of
androgen receptor action in breast cancer cell lines. Breast Cancer
Res. 16:R212014. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lattrich C, Schüler S, Häring J,
Skrzypczak M, Ortmann O and Treeck O: Effects of a combined
treatment with tamoxifen and estrogen receptor β agonists on human
breast cancer cell lines. Arch Gynecol Obstet. 289:163–171. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hartman J, Lindberg K, Morani A, Inzunza
J, Ström A and Gustafsson JA: Estrogen receptor beta inhibits
angiogenesis and growth of T47D breast cancer xenografts. Cancer
Res. 66:11207–11213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang H, Zhang Z, Xuan L, Zheng S, Guo L,
Zhan Q, Qu X, Zhang B, Wang Y, Wang X, et al: Evaluation of ER-α,
ER-Β1 and ER-Β2 expression and correlation with clinicopathologic
factors in invasive luminal subtype breast cancers. Clin Transl
Oncol. 14:225–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Honma N, Horii R, Iwase T, Saji S, Younes
M, Takubo K, Matsuura M, Ito Y, Akiyama F and Sakamoto G: Clinical
importance of estrogen receptor-beta evaluation in breast cancer
patients treated with adjuvant tamoxifen therapy. J Clin Oncol.
26:3727–3734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Borgquist S, Holm C, Stendahl M,
Anagnostaki L, Landberg G and Jirström K: Oestrogen receptors alpha
and beta show different associations to clinicopathological
parameters and their co-expression might predict a better response
to endocrine treatment in breast cancer. J Clin Pathol. 61:197–203.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shaaban AM, Green AR, Karthik S, Alizadeh
Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders
PT, et al: Nuclear and cytoplasmic expression of ERbeta1, ERbeta2,
and ERbeta5 identifies distinct prognostic outcome for breast
cancer patients. Clin Cancer Res. 14:5228–5235. 2008. View Article : Google Scholar : PubMed/NCBI
|
